INDBInternet News Database 2.5 Updated 1 min ago · 282 sources Show or hide images Light or dark

Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD

    (MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...

Comments

Comments need JavaScript.